Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of MDK-703 in Healthy Volunteers
NCT05366634Phase 1Completed
- Sponsor
- Medikine, Inc.
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of MDK-703 in solid tumor (3 cohorts), sponsored by Medikine, Inc. Primary endpoint: Assessment of adverse events at 8 weeks. Started Jun 2022; status: completed.
02
Drugs
MDK-703
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05366634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366634.